Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based CFO’ operating in the Biopharma space. If you think a CFO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Duncan Kennedy
Chief Financial Officer of BTG International
Duncan Kennedy joined BTG in December 2005 as Group Financial Controller and in April 2012 he joined the Leadership Team as Group Director of Finance, with management responsibility for the global finance function. Duncan led BTG’s Interventional Oncology business from May 2015 until he began as CFO in January 2018. Prior to joining BTG, Duncan spent six years in the group finance function of Wembley plc, an international leisure group, gaining wide-ranging experience in all aspects of listed company financial reporting and significant involvement in corporate transactions. Duncan qualified as a Chartered Accountant at Arthur Andersen and holds a BSc in Mathematics from Durham University.
Follow Duncan Kennedy:
About BTG International: BTG is a global healthcare company focused on Interventional Medicine.
Anne Hyland
Chief Financial Officer & Company Secretary of Kymab
Hyland has a strong track record within the biopharma sector, bringing with her over 25 years of financial experience with both public and private companies. Most recently, she served as Chief Financial Officer of BBI Diagnostics Group Ltd and FTSE-listed Vectura Group plc (LSE: VEC). Ms Hyland currently serves as Non-executive Director and Chair of the Audit Committee of the global pharmaceutical and services company, Clinigen Group plc (AIM:CLIN). Prior to Vectura, she held a number of senior finance position, including Director of Corporate Finance at the then FTSE 100 Celltech Group plc, Medeva plc and KPMG. Ms Hyland is a Chartered Accountant (FCA), a Corporate Tax Adviser (CTA–AITI) and holds a degree in business studies from Trinity College, Dublin.
Follow Anne Hyland:
About Kymab: Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics.
Anjum Ahmad
CFO of Touchlight Genetics
Follow Anjum Ahmad:
About Touchlight Genetics: Touchlight Genetics, a British bio-pharmaceutical company founded in 2007.
Jayesh Pankhania
Chief Financial Officer of Horizon Discovery
Jayesh joined Xtera in February 2017 with over 25 years’ senior finance experience having started his career with PwC. He has since held senior roles in public quoted and privately owned companies, rising rapidly to the CFO role in his latest two positions, most recently with the HOC Group, a $150M privately owned construction group. Prior to that he was with Asia Resource Minerals PLC (Group Turnover >$1B) as Deputy CFO. Jayesh was responsible for improving corporate governance and financial controls in both cases. Jayesh attended the University of East Anglia studying Accountancy, holds an MBA from the London Business School and is a Fellow of the Institute of Chartered Accountants in England and Wales.
Follow Jayesh Pankhania:
About Horizon Discovery: Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.
Doug Quinn
Chief Financial Officer of SkinBioTherapeutics plc
Follow Doug Quinn:
About SkinBioTherapeutics plc, Videregen: Developing and commercialising its SkinBiotix technology platform
